XOMA (XOMAP) Competitors

$25.41 +0.17 (+0.67%)

As of 03:15 PM Eastern

XOMAP vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

Should you be buying XOMA stock or one of its competitors? The main competitors of XOMA include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.

How does XOMA compare to Ainos?

XOMA (NASDAQ:XOMAP) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

: Company Net Margins Return on Equity Return on Assets
XOMA N/A N/A N/A
Ainos N/A N/A N/A
: In the previous week, XOMA had 2 more articles in the media than Ainos. MarketBeat recorded 2 mentions for XOMA and 0 mentions for Ainos. XOMA's average media sentiment score of 0.00 equaled Ainos'average media sentiment score.
Company Overall Sentiment
XOMA Neutral
Ainos Neutral
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XOMA $11.66M N/A N/A N/A N/A
Ainos $124.16K N/A N/A N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
XOMA	N/A	N/A	N/A
Ainos	N/A	N/A	N/A

Company	Overall Sentiment
XOMA	Neutral
Ainos	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA	$11.66M	N/A	N/A	N/A	N/A
Ainos	$124.16K	N/A	N/A	N/A	N/A

Summary

XOMA beats Ainos on 2 of the 2 factors compared between the two stocks.

How does XOMA compare to Alvotech?

XOMA (NASDAQ:XOMAP) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XOMA $11.66M N/A N/A N/A N/A
Alvotech $586.32M N/A N/A N/A N/A
: Company Net Margins Return on Equity Return on Assets
XOMA N/A N/A N/A
Alvotech N/A N/A N/A
: In the previous week, XOMA had 2 more articles in the media than Alvotech. MarketBeat recorded 2 mentions for XOMA and 0 mentions for Alvotech. XOMA's average media sentiment score of 0.00 equaled Alvotech'saverage media sentiment score.
Company Overall Sentiment
XOMA Neutral
Alvotech Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA	$11.66M	N/A	N/A	N/A	N/A
Alvotech	$586.32M	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
XOMA	N/A	N/A	N/A
Alvotech	N/A	N/A	N/A

Company	Overall Sentiment
XOMA	Neutral
Alvotech	Neutral

Summary

XOMA and Alvotech tied by winning 1 of the 2 factors compared between the two stocks.

How does XOMA compare to Aravive?

XOMA (NASDAQ:XOMAP) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

: XOMA has higher revenue and earnings than Aravive.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XOMA $11.66M N/A N/A N/A N/A
Aravive $6.99M 0.42 -$66.21M -$0.90 N/A
: 35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Company Net Margins Return on Equity Return on Assets
XOMA N/A N/A N/A
Aravive N/A N/A N/A
: In the previous week, XOMA had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for XOMA and 0 mentions for Aravive. XOMA's average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.
Company Overall Sentiment
XOMA Neutral
Aravive Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA	$11.66M	N/A	N/A	N/A	N/A
Aravive	$6.99M	0.42	-$66.21M	-$0.90	N/A

Company	Net Margins	Return on Equity	Return on Assets
XOMA	N/A	N/A	N/A
Aravive	N/A	N/A	N/A

Company	Overall Sentiment
XOMA	Neutral
Aravive	Neutral

Summary

XOMA and Aravive tied by winning 2 of the 4 factors compared between the two stocks.

How does XOMA compare to Atlantic Coastal Acquisition Corp. II?

XOMA (NASDAQ:XOMAP) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

: Company Net Margins Return on Equity Return on Assets
XOMA N/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A
: In the previous week, XOMA had 2 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 2 mentions for XOMA and 0 mentions for Atlantic Coastal Acquisition Corp. II. XOMA's average media sentiment score of 0.00 equaled Atlantic Coastal Acquisition Corp. II'saverage media sentiment score.
Company Overall Sentiment
XOMA Neutral
Atlantic Coastal Acquisition Corp. II Neutral
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XOMA $11.66M N/A N/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
XOMA	N/A	N/A	N/A
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A

Company	Overall Sentiment
XOMA	Neutral
Atlantic Coastal Acquisition Corp. II	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA	$11.66M	N/A	N/A	N/A	N/A
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A

Summary

XOMA beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does XOMA compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and XOMA (NASDAQ:XOMAP) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

: XOMA has lower revenue, but higher earnings than Avidity Biosciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avidity Biosciences $18.62M N/A -$322.30M N/A N/A
XOMA $11.66M N/A N/A N/A N/A
: Avidity Biosciences presently has a consensus target price of $69.42, indicating a potential upside of 437.73%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Avidity Biosciences is more favorable than XOMA.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.32
XOMA
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: XOMA has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. XOMA's return on equity of 0.00% beat Avidity Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Avidity Biosciences -3,650.39% -44.92% -39.57%
XOMA N/A N/A N/A
: In the previous week, XOMA had 1 more articles in the media than Avidity Biosciences. MarketBeat recorded 2 mentions for XOMA and 1 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.00 equaled XOMA'saverage media sentiment score.
Company Overall Sentiment
Avidity Biosciences Neutral
XOMA Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$18.62M	N/A	-$322.30M	N/A	N/A
XOMA	$11.66M	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32
XOMA	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
XOMA	N/A	N/A	N/A

Company	Overall Sentiment
Avidity Biosciences	Neutral
XOMA	Neutral

Summary

Avidity Biosciences beats XOMA on 5 of the 9 factors compared between the two stocks.

Get XOMA News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XOMAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XOMAP vs. The Competition

Export

Metric	XOMA	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	N/A	$443.28M	$6.25B	$11.87B
Dividend Yield	9.29%	3.86%	2.73%	5.21%
P/E Ratio	N/A	4.19	29.03	28.47
Price / Sales	N/A	6,879.71	476.10	60.92
Price / Cash	N/A	13.13	27.62	36.52
Price / Book	N/A	77.74	9.67	6.67
Net Income	N/A	-$96.07M	$3.55B	$332.53M
7 Day Performance	0.63%	0.51%	1.75%	2.03%
1 Month Performance	-6.18%	3.62%	5.66%	9.23%
1 Year Performance	-1.13%	47.92%	34.42%	39.62%

XOMA Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XOMAP XOMA	N/A	$25.41 +0.7%	N/A	N/A	$0.00	$11.66M	N/A	10
AIMDW Ainos	N/A	$0.11 flat	N/A	N/A	$0.00	$124.16K	N/A	40	Positive News
ALVOW Alvotech	N/A	$0.21 -18.2%	N/A	N/A	$0.00	$586.32M	N/A	4	Positive News Upcoming Earnings Gap Up High Trading Volume
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
ACABW Atlantic Coastal Acquisition Corp. II	N/A	$0.00 flat	N/A	N/A	$0.00	N/A	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XOMAP) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XOMA (XOMAP) Competitors